arrow
S

Susumu Kobayashi

Harvard Medical School
H指数:76
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development and validation of a plasma miRNA-CEA biomarker panel for early detection of lung cancer

血浆miRNA-CEA生物标志物面板的开发与验证用于肺癌的早期检测

2026-05-010
OAAI
Coopting germline BRCA2 mutation with an available PARP inhibitor to manage resistance to EGFR targeted therapy in EGFR-mutated lung cancer: combination of olaparib with osimertinib

利用可用的PARP抑制剂招募胚系BRCA2突变,以管理EGFR突变型肺癌中针对EGFR靶向治疗的耐药性:奥拉帕利与奥希替尼的联合方案

2026-02-240
PRE
A quantitative SPECT/CT metric for diagnosing transthyretin cardiac amyloidosis: multicenter study on biopsy-confirmed cases

一种用于诊断甲状腺素转运蛋白心肌淀粉样变性的定量SPECT/CT指标:基于活检确诊病例的多中心研究

2025-04-240
PRE
Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)

EGFR酪氨酸激酶抑制剂在携带EGFR外显子19插入突变的非小细胞肺癌患者中的疗效:基于LC-SCRUM-Asia(多机构基因组筛查登记)的临床-基因组学及体外研究分析

2025-04-010
OAAI
WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer

WEE1使非小细胞肺癌对KRASG12C抑制剂产生耐药性

2025-02-011
PRE
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation
2024-01-297
OAAI
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates

肺癌中的EGFR外显子20插入突变和ERBB2突变: 从口服激酶抑制剂到抗体-药物结合物的已批准靶向治疗的叙述性综述

2023-07-0116
OAAI